在於我們是
2021-12-17
Please like
[Smile]
CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>疾病预防控制中心顾问推荐辉瑞和 Moderna Covid-19 疫苗，而不是强生公司</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690544725,"tweetId":"690544725","gmtCreate":1639697496129,"gmtModify":1639697496536,"author":{"id":3580638845558081,"idStr":"3580638845558081","authorId":3580638845558081,"authorIdStr":"3580638845558081","name":"在於我們是","avatar":"https://static.tigerbbs.com/400933d41d715fa2dc89a42f82e63f64","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":32,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Please like <span>[Smile] </span></p></body></html>","htmlText":"<html><head></head><body><p>Please like <span>[Smile] </span></p></body></html>","text":"Please like [Smile]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690544725","repostId":1154960652,"repostType":4,"repost":{"id":"1154960652","kind":"news","pubTimestamp":1639695603,"share":"https://www.laohu8.com/m/news/1154960652?lang=zh_CN&edition=full","pubTime":"2021-12-17 07:00","market":"us","language":"en","title":"CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>疾病预防控制中心顾问推荐辉瑞和 Moderna Covid-19 疫苗，而不是强生公司</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960652","media":"The Wall Street Journal","summary":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moder","content":"<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司（Pfizer Inc. PFE 4.17%）或 Moderna Inc. MRNA -0.44% 而不是强生公司（Johnson & Johnson）的 JNJ 1.09% 的 Covid-19 疫苗，此前卫生当局表示，一种罕见但严重的血液凝固疾病的发病率高于以前检测到的发病率。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>免疫实践咨询委员会周四以15比0的投票结果提出了这一建议，此前该委员会听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生注射的使用造成另一个打击，强生注射的吸收受到了制造问题和早期关于凝血状况的报道的损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>疾病预防控制中心官员周四表示，美国强生疫苗接种者中至少有54例这种疾病，即血栓形成伴血小板减少综合征，或TTS，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们说，男性和女性的病例率都高于之前估计的水平，而且年龄范围更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“委员会成员巴勃罗-桑切斯（Pablo Sanchez）说：”我只是不能推荐与可能导致死亡的疾病相关的疫苗。</blockquote></p><p> J&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.</p><p><blockquote>强生表示，它对其疫苗的总体积极效益风险状况仍然充满信心。“强生公司制药研发全球主管马泰-马门（Mathai Mammen）说：”使用强生疫苗的人的安全和福祉仍然是我们的首要任务。</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他说，该公司将与疾病预防控制中心合作采取下一步措施，并大力支持关于TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生公司的 Covid-19 疫苗基于与辉瑞和 Moderna 疫苗中使用的信使 RNA 不同的技术。</blockquote></p><p> J&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生公司的疫苗包括一种可引起普通感冒的无害病毒，这种病毒经过设计，含有引发冠状病毒免疫反应的基因指令。mRNA 疫苗不含任何病毒物质，采用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查 TTS 病情时暂停了强生公司疫苗的使用。在卫生当局得出结论，该疫苗的益处仍然大于风险后，该疫苗于 4 月份恢复使用。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为疾病预防控制中心提供疫苗政策建议的 ACIP 在召开两次会议讨论这一问题后，于 4 月份投票决定恢复使用强生公司的疫苗。发给疫苗提供者和接受者的情况说明书中增加了有关风险的警告，包括30至49岁的女性风险最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁之间的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>疾病预防控制中心官员在顾问会议上说，截至 8 月 31 日，所有接种者每接种 100 万剂强生疫苗，就会报告约 3.8 例 TTS 病例。30至39岁的女性发病率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>疾控中心官员还表示，在那些发展TTS的人中，死亡率约为15%。官员们说，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>疾病预防控制中心官员说，接种强生疫苗仍然优于不接种疫苗，但辉瑞-BioNTech 和 Moderna 的信使 RNA 疫苗在益处和风险之间的平衡优于强生疫苗。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP 的建议对疫苗提供者或接种者没有约束力，但它将具有相当大的分量，因为委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，强生疫苗应继续提供给无法接种 mRNA 疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或者对一剂这些疫苗有严重过敏反应的人，不应该接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗还具有引起心脏炎症（包括心肌炎）的风险，特别是在30岁以下的男性中。然而，卫生官员表示，预防新冠肺炎住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>J&J疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监控疫苗的安全性，包括TTS风险。她说，疫苗是一种救命工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分原因是出于安全考虑，强生公司的单剂量疫苗的使用量远低于 Moderna 和辉瑞公司及其合作伙伴 BioNTech SE 生产的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.</p><p><blockquote>据美国疾病预防控制中心称，美国约有 1610 万人接种了强生公司的疫苗。强生公司的疫苗已接种约 87 万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗加强剂和2400万剂Moderna加强剂。</blockquote></p><p> J&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生公司周四表示，它最近更新了疫苗的情况说明书，称在接种过强生疫苗或其他具有类似腺病毒设计的疫苗后，不应给以前患过 TTS 的人接种该疫苗。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他采用类似设计的疫苗包括阿斯利康公司（AstraZeneca PLC）的 Covid-19 疫苗，该疫苗在美国境外上市，但在美国境内不可用。</blockquote></p><p> The recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.</p><p><blockquote>该建议有可能影响美国以外地区对强生疫苗的支持，包括在努力增加疫苗供应的国家，而强生已经开始运送默克公司帮助生产的疫苗。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.</p><p><blockquote>疾病预防控制中心咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是这样的举动可能会削弱人们对强生疫苗的信心，而不是 mRNA 疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>疾病预防控制中心顾问推荐辉瑞和 Moderna Covid-19 疫苗，而不是强生公司</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>疾病预防控制中心顾问推荐辉瑞和 Moderna Covid-19 疫苗，而不是强生公司</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-17 07:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司（Pfizer Inc. PFE 4.17%）或 Moderna Inc. MRNA -0.44% 而不是强生公司（Johnson & Johnson）的 JNJ 1.09% 的 Covid-19 疫苗，此前卫生当局表示，一种罕见但严重的血液凝固疾病的发病率高于以前检测到的发病率。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>免疫实践咨询委员会周四以15比0的投票结果提出了这一建议，此前该委员会听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生注射的使用造成另一个打击，强生注射的吸收受到了制造问题和早期关于凝血状况的报道的损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>疾病预防控制中心官员周四表示，美国强生疫苗接种者中至少有54例这种疾病，即血栓形成伴血小板减少综合征，或TTS，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们说，男性和女性的病例率都高于之前估计的水平，而且年龄范围更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“委员会成员巴勃罗-桑切斯（Pablo Sanchez）说：”我只是不能推荐与可能导致死亡的疾病相关的疫苗。</blockquote></p><p> J&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.</p><p><blockquote>强生表示，它对其疫苗的总体积极效益风险状况仍然充满信心。“强生公司制药研发全球主管马泰-马门（Mathai Mammen）说：”使用强生疫苗的人的安全和福祉仍然是我们的首要任务。</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他说，该公司将与疾病预防控制中心合作采取下一步措施，并大力支持关于TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生公司的 Covid-19 疫苗基于与辉瑞和 Moderna 疫苗中使用的信使 RNA 不同的技术。</blockquote></p><p> J&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生公司的疫苗包括一种可引起普通感冒的无害病毒，这种病毒经过设计，含有引发冠状病毒免疫反应的基因指令。mRNA 疫苗不含任何病毒物质，采用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查 TTS 病情时暂停了强生公司疫苗的使用。在卫生当局得出结论，该疫苗的益处仍然大于风险后，该疫苗于 4 月份恢复使用。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为疾病预防控制中心提供疫苗政策建议的 ACIP 在召开两次会议讨论这一问题后，于 4 月份投票决定恢复使用强生公司的疫苗。发给疫苗提供者和接受者的情况说明书中增加了有关风险的警告，包括30至49岁的女性风险最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁之间的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>疾病预防控制中心官员在顾问会议上说，截至 8 月 31 日，所有接种者每接种 100 万剂强生疫苗，就会报告约 3.8 例 TTS 病例。30至39岁的女性发病率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>疾控中心官员还表示，在那些发展TTS的人中，死亡率约为15%。官员们说，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>疾病预防控制中心官员说，接种强生疫苗仍然优于不接种疫苗，但辉瑞-BioNTech 和 Moderna 的信使 RNA 疫苗在益处和风险之间的平衡优于强生疫苗。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP 的建议对疫苗提供者或接种者没有约束力，但它将具有相当大的分量，因为委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，强生疫苗应继续提供给无法接种 mRNA 疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或者对一剂这些疫苗有严重过敏反应的人，不应该接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗还具有引起心脏炎症（包括心肌炎）的风险，特别是在30岁以下的男性中。然而，卫生官员表示，预防新冠肺炎住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>J&J疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监控疫苗的安全性，包括TTS风险。她说，疫苗是一种救命工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分原因是出于安全考虑，强生公司的单剂量疫苗的使用量远低于 Moderna 和辉瑞公司及其合作伙伴 BioNTech SE 生产的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.</p><p><blockquote>据美国疾病预防控制中心称，美国约有 1610 万人接种了强生公司的疫苗。强生公司的疫苗已接种约 87 万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗加强剂和2400万剂Moderna加强剂。</blockquote></p><p> J&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生公司周四表示，它最近更新了疫苗的情况说明书，称在接种过强生疫苗或其他具有类似腺病毒设计的疫苗后，不应给以前患过 TTS 的人接种该疫苗。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他采用类似设计的疫苗包括阿斯利康公司（AstraZeneca PLC）的 Covid-19 疫苗，该疫苗在美国境外上市，但在美国境内不可用。</blockquote></p><p> The recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.</p><p><blockquote>该建议有可能影响美国以外地区对强生疫苗的支持，包括在努力增加疫苗供应的国家，而强生已经开始运送默克公司帮助生产的疫苗。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.</p><p><blockquote>疾病预防控制中心咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是这样的举动可能会削弱人们对强生疫苗的信心，而不是 mRNA 疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154960652","content_text":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.\n\nThe Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.\n\nThe updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.\n\nThere have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.\n\nThe rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.\n\n“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.\n\nJ&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.\n\nHe said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.\n\nJ&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.\n\nJ&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.\n\nEarlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.\n\nThe ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.\nAt that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.\n\nAs of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.\n\nCDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.\n\nCDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.\n\nA recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.\n\n\nSome committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.\n\nHealth officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.\n\nThe mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.\n\nPenny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.\n\nPartly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.\n\nAbout 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.\n\nMore than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.\n\nJ&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.\n\nOther shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.\n\nThe recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.\n\nThe CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3005,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690544725"}
精彩评论